ERBB2 and breast carcinoma: They utilized the FoundationOneTM 236-gene targeted sequencing panel and standard of care biomarker test results (such as ER, PR, and HER2 IHC for breast cancer) to inform treatment selection for commercially available therapies and clinical trial enrollment.